Safety And Efficacy Outcomes With Nivolumab Plus Ipilimumab In Patients With Advanced Renal Cell Carcinoma And Low Karnofsky Performance Status: Results From The Checkmate 920 Trial.

Thomas E. Hutson,Bradley Curtis Carthon,Jeffrey Yorio,Sunil Babu,Heidi Ann McKean,Ivor John Percent,Scott S. Tykodi,Michael Roger Harrison,Joshua Zhang,Jesus Zoco,Jennifer L. Johansen,Daniel J. George

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 3|浏览0

暂无评分

摘要

315Background: Combination therapy with nivolumab + ipilimumab (NIVO+IPI) has demonstrated long-term efficacy and tolerability for patients (pts) with previously untreated advanced renal cell carci...

查看译文

关键词

advanced renal cell carcinoma,renal cell carcinoma,nivolumab,ipilimumab,low karnofsky performance status

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要